Circulating syndecan-1 is reduced in pregnancies with poor fetal growth and its secretion regulated by matrix metalloproteinases and the mitochondria

D Garcha; SP Walker; TM MacDonald; J Hyett; J Jellins; J Myers; SE Illanes; JK Nien; M Schepeler; E Keenan; CA Whigham; P Cannon; E Murray; TV Nguyen; M Kandel; J Masci; C Murphy; T Cruickshank; N Pritchard; NJ Hannan; F Brownfoot; A Roddy Mitchell; A Middleton; G Pell; GP Wong; S Tong; TJ Kaitu’u-Lino

Journal article

Circulating syndecan-1 is reduced in pregnancies with poor fetal growth and its secretion regulated by matrix metalloproteinases and the mitochondria

D Garcha, SP Walker, TM MacDonald, J Hyett, J Jellins, J Myers, SE Illanes, JK Nien, M Schepeler, E Keenan, CA Whigham, P Cannon, E Murray, TV Nguyen, M Kandel, J Masci, C Murphy, T Cruickshank, N Pritchard, NJ Hannan Show all

Scientific Reports | Published : 2021

DOI: 10.1038/s41598-021-96077-1

Open access

Download PDF

Abstract

Fetal growth restriction is a leading cause of stillbirth that often remains undetected during pregnancy. Identifying novel biomarkers may improve detection of pregnancies at risk. This study aimed to assess syndecan-1 as a biomarker for small for gestational age (SGA) or fetal growth restricted (FGR) pregnancies and determine its molecular regulation. Circulating maternal syndecan-1 was measured in several cohorts; a large prospective cohort collected around 36 weeks’ gestation (n = 1206), a case control study from the Manchester Antenatal Vascular service (285 women sampled at 24–34 weeks’ gestation); two prospective cohorts collected on the day of delivery (36 + 3–41 + 3 weeks’ gestation,..

View full abstract

University of Melbourne Researchers

Susan Walker Author

Teresa MacDonald Author

Emerson Keenan Author

Ping Cannon Author

Related Projects (4)

IMPROVING THE PREDICTION AND DETECTION OF CONTRIBUTORS TO TERM STILLBIRTH

Stillbirths are a global human tragedy, with 1 in 130 of all pregnancies in Australia ending in stillbirth. We propose to use ultrasound and..

DEVELOPMENT OF NOVEL THERAPEUTICS TO PREVENT OR TREAT PREECLAMPSIA

Preeclampsia, a major pregnancy complication, affects ~3-8% of pregnancies. There is no cure. We have developed new strategies to tackle the..

NEW DIAGNOSTICS TO PREDICT PREECLAMPSIA AND FETAL GROWTH RESTRICTION

Preeclampsia and fetal growth restriction are two of the most serious complications of pregnancy, claiming the lives of tens of thousands of..

TRANSLATING NEW THERAPEUTICS AND DIAGNOSTICS FOR MAJOR PREGNANCY COMPLICATIONS

My research is focussed on tackling major complications of pregnancy that are a threat to the lives of both mother’s and babies. We are deve..

Grants

Awarded by RANZCOG Research Foundation

Funding Acknowledgements

Funding for this work was provided by the National Health and Medical Research Council (#1065854, #1183854, #116071), an Australian Government Research Training Program Scholarship, and RANZCOG Taylor Hammond Scholarship to TM; National Health and Medical Research Council Fellowships to TKL (#1159261), NJH (#1146128), ST (#1136418). The funders played no role in study design or analysis.